DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Up 28.4% in December

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) was the recipient of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 194,600 shares, a growth of 28.4% from the November 30th total of 151,500 shares. Based on an average trading volume of 87,500 shares, the short-interest ratio is currently 2.2 days.

Institutional Investors Weigh In On DiaMedica Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Blue Trust Inc. purchased a new position in shares of DiaMedica Therapeutics in the 3rd quarter worth about $185,000. Magnolia Capital Advisors LLC bought a new stake in DiaMedica Therapeutics during the 2nd quarter valued at about $87,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in DiaMedica Therapeutics in the third quarter worth about $40,000. Finally, Geode Capital Management LLC lifted its stake in shares of DiaMedica Therapeutics by 29.6% in the third quarter. Geode Capital Management LLC now owns 306,958 shares of the company’s stock worth $1,286,000 after buying an additional 70,070 shares in the last quarter. 10.12% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of DiaMedica Therapeutics in a report on Friday, November 15th.

DiaMedica Therapeutics Stock Down 1.3 %

Shares of DMAC opened at $5.34 on Tuesday. The stock has a market cap of $228.34 million, a P/E ratio of -9.54 and a beta of 1.51. The business’s 50 day moving average price is $4.80 and its 200-day moving average price is $4.04. DiaMedica Therapeutics has a 52 week low of $2.14 and a 52 week high of $6.41.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.